Last reviewed: June 30, 2026

Last updated: June 30, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Both Zepbound and Wegovy are FDA-approved GLP-1 receptor agonists, but they work through different pathways in your body. Clinical trials show Zepbound (tirzepatide) produces approximately 22% body weight reduction, while Wegovy (semaglutide) achieves roughly 15% reduction over similar timeframes. Your choice depends on personal response, medical history, and treatment goals.

How Zepbound and Wegovy Differ in Mechanism

Wegovy contains semaglutide, which activates the GLP-1 receptor alone. This signal tells your brain you are full, slows stomach emptying, and reduces hunger hormones like ghrelin. Semaglutide has been studied extensively since its diabetes approval in 2017, giving it a long safety record in weight management.

Zepbound uses tirzepatide, a dual-action molecule that activates both GLP-1 and GIP receptors simultaneously. The GIP pathway adds an additional metabolic signal, enhancing satiety and energy expenditure beyond what semaglutide alone provides. This dual mechanism explains why tirzepatide often delivers stronger weight loss results in head-to-head comparisons.

Clinical Trial Results: Zepbound Versus Wegovy

The STEP trial program for Wegovy enrolled over 4,500 patients across four studies. Average weight loss ranged from 15% to 18% of baseline body weight when combined with lifestyle changes. Patients also saw improvements in blood sugar, blood pressure, and cardiovascular risk markers.

The SURMOUNT trial series tested tirzepatide in similar populations. Participants achieved 20% to 22% weight loss at the highest maintenance dose, with some subgroups exceeding 25%. The GIP receptor activation appears to amplify appetite suppression and may improve metabolic rate slightly more than semaglutide alone.

Neither medication is universally superior—individual genetics, baseline metabolism, and lifestyle factors determine which works better for you. Some patients respond equally well to both; others see dramatic differences. Genetic testing can help predict your likely response before starting treatment.

Cost and Access: Injectable Versus Oral Options

Zepbound carries a significant retail price, often exceeding $1,000 per month without insurance. Wegovy pricing is similarly high. PlexusDx offers compounded tirzepatide injections starting at $249 per month through licensed 503A pharmacies, alongside compounded semaglutide injections from $149 per month. Both are HSA/FSA eligible with no membership fees.

Beyond injections, PlexusDx provides oral formulations of both compounds. Oral tirzepatide begins at $279 monthly, while oral semaglutide starts at $249 monthly. Oral options appeal to needle-averse patients, though injectable versions typically achieve higher blood levels and faster satiety onset.

Personalization: Finding Your Ideal GLP-1 Match

Genetic variation significantly influences GLP-1 therapy response. Certain variants in the GLP1R gene affect receptor sensitivity; FTO gene variants correlate with baseline appetite and weight gain risk; MC4R variants influence energy expenditure pathways. GIPR variants specifically predict tirzepatide responsiveness.

PlexusDx Precision Peptide Genetic Test ($99 add-on after month one) maps 14 metabolic pathways across 49 peptides and 150+ genetic insights. This test identifies your genetic predispositions for satiety, insulin sensitivity, and GLP-1 versus GIP receptor responsiveness. Armed with this data, your provider can recommend semaglutide, tirzepatide, or PlexusDx GLP-Squared (both compounds together) with greater confidence in your metabolic profile.

Side Effects and Tolerability Comparison

Both medications share common side effects: nausea, vomiting, constipation, and diarrhea. These are dose-dependent and typically improve within weeks as your body adapts. Tirzepatide users report slightly more gastrointestinal adjustments at dose initiation, likely due to dual-pathway activation. Rare reports of pancreatitis and gallbladder issues exist with both compounds, though causation remains debated.

Injection site reactions (mild redness, swelling) occur in under 5% of users with either medication. Oral formulations bypass injection concerns but may cause more nausea initially since they pass through the digestive system. PlexusDx recommends starting at lower doses and advancing gradually—your dose may increase, but your flat monthly price remains constant across all strength levels.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Which medication causes more weight loss: Zepbound or Wegovy?

Clinical trials show tirzepatide (Zepbound) produces approximately 22% body weight reduction versus 15% for semaglutide (Wegovy) over comparable periods. However, individual results vary significantly based on genetics, adherence, and lifestyle. Genetic testing through PlexusDx can help predict your likely response before starting either medication.

Can I switch from Wegovy to Zepbound if I am not losing weight?

Yes. If semaglutide plateaus or produces insufficient results, many providers transition patients to tirzepatide. The dual GIP/GLP-1 mechanism may unlock better results in non-responders. This switch typically involves a short washout period and dose titration. PlexusDx supports both transitions with compounded versions of each medication.

How much does PlexusDx tirzepatide cost compared to Zepbound?

PlexusDx compounded tirzepatide injections start at $249 per month—a fraction of Zepbound's retail price. PlexusDx serves all 50 states, requires no insurance, and accepts HSA/FSA funds. Your dose may increase over time, but your monthly price stays flat across all strength levels.

Are compounded GLP-1 medications as safe as Zepbound and Wegovy?

PlexusDx sources all compounded medications from licensed 503A pharmacies, which operate under strict FDA oversight and quality standards. While compounded medications are not FDA-approved, they are FDA-regulated for safety and purity. Both brand and compounded versions contain identical active molecules.

Does PlexusDx genetic testing predict whether tirzepatide or semaglutide will work better?

Yes. PlexusDx Precision Peptide Genetic Test identifies your variants in GLP1R, GIPR, FTO, and MC4R genes—key predictors of tirzepatide versus semaglutide response. The test maps 150+ metabolic insights across 14 pathways to inform personalized treatment selection, available at $99 after your first month of therapy.

Related Reading

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake

~60 seconds · $0 charged until your provider approves